SS-31 50 mg

SS-31 50 mg contains elamipretide, a mitochondria-targeted peptide. It is FDA-approved for Barth syndrome, a rare genetic mitochondrial disorder. In non-medical research contexts, it is commonly referenced for supporting mitochondrial bioenergetics and reducing oxidative stress, though such use falls outside approved indications.

Clinical trials have used 40 mg per day subcutaneously for rare mitochondrial diseases. Community protocols commonly reference 5–10 mg per day subcutaneously. Morning administration is typical for energy support, while pre-workout dosing is referenced for performance applications.

No. SS-31 does not bind to cell surface receptors and does not suppress the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, and post-cycle therapy in the context of testosterone recovery is not applicable.

SS-31 binds to cardiolipin on the inner mitochondrial membrane, preventing cardiolipin from converting cytochrome c into a peroxidase while protecting its electron-carrying function. This stabilizes mitochondrial cristae structure and promotes oxidative phosphorylation. SS-31 does not bind to cell surface receptors and has no known receptor-mediated effects.

Most users report feeling nothing in the first week. Mitochondrial changes take 2 to 3 weeks to accumulate, and by week 3 or 4 users may notice improved stamina in their last set. The peptide is not a stimulant, and effects are judged over weeks via recovery and energy, not a 20-minute “feel”.

There is no single “best” mitochondrial peptide. SS-31 is the first FDA-approved mitochondrial peptide, with a cardiolipin-binding mechanism. MOTS-c acts through AMPK activation and nuclear gene regulation, complementing SS-31’s membrane-stabilizing role. The appropriate choice depends on individual goals.

SS-31 is a cardiolipin-binding peptide that stabilizes the inner mitochondrial membrane and optimizes electron transport chain function. MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates nuclear gene expression. They are often stacked together as complementary “structural engineer” and “operations manager” compounds.

SS-31 targets cardiolipin on the inner mitochondrial membrane to support cellular energy production. BPC 157 is a research peptide studied for tissue repair through angiogenesis and collagen synthesis. The two act through entirely different pathways and are sometimes referenced together in recovery-focused protocols.

10 mg is at the upper end of community reference ranges, which typically span 5–10 mg per day. Clinical trials for rare diseases have used 40 mg per day. The 50 mg vial provides multiple doses at community reference levels.

SS-31 50 mg is labeled at 50 mg of SS-31 (Elamipretide) per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized SS-31 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.